Other studies showed that FOXM1 and its downstream DNA damage repair targets BRCA1, BRCA2, and XRCC1 increased cisplatin resistance in different types of cancer cells [16-18], as well as herceptin and paclitaxel [19] resistance in breast cancer cells. The gene discussed is FOXM1; the disease is cancer.